[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know",
    "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=c53e2da5e38bfbd124e770a87a9e444636d73614a78d1d462fcbf0bad2f2b99f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753221605,
      "headline": "Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know",
      "id": 136038381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $470.13, denoting a +2.54% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=c53e2da5e38bfbd124e770a87a9e444636d73614a78d1d462fcbf0bad2f2b99f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
    "url": "https://finnhub.io/api/news?id=30ffe9bb47e58c18a9c9e27fa68d8820c770e689ac2b31d0dfd8e149ee0eb14f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753203300,
      "headline": "Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 136033557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
      "url": "https://finnhub.io/api/news?id=30ffe9bb47e58c18a9c9e27fa68d8820c770e689ac2b31d0dfd8e149ee0eb14f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=334c63f9b7ced34e093ea8b98e16e390dc916a24dcf1bc97adbd89e66bb131ea",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753202280,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136049003,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=334c63f9b7ced34e093ea8b98e16e390dc916a24dcf1bc97adbd89e66bb131ea"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know",
    "summary": "Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust triple-digit earnings growth.",
    "url": "https://finnhub.io/api/news?id=1d9e827cae3a7c5545492f55569f88733941499d502dcd2b248fa2723c2c6579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753184300,
      "headline": "Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know",
      "id": 136031646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust triple-digit earnings growth.",
      "url": "https://finnhub.io/api/news?id=1d9e827cae3a7c5545492f55569f88733941499d502dcd2b248fa2723c2c6579"
    }
  },
  {
    "ts": null,
    "headline": "GreensKeeper Value Fund Q2 2025 Letter",
    "summary": "GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when others chase hype.",
    "url": "https://finnhub.io/api/news?id=088040f4d5da88e72b06ff2ba21db4bb9a524f27a220fae8670d4b6eec1939f4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753177800,
      "headline": "GreensKeeper Value Fund Q2 2025 Letter",
      "id": 136031607,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217643493/image_2217643493.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when others chase hype.",
      "url": "https://finnhub.io/api/news?id=088040f4d5da88e72b06ff2ba21db4bb9a524f27a220fae8670d4b6eec1939f4"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results",
    "summary": "Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials.  Shares of these drugmakers could jump if the data from the studies is positive.  Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials.",
    "url": "https://finnhub.io/api/news?id=481153932dcd0a118d9a0418223142728ca633111da836c0879efeeca1e73c97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753172040,
      "headline": "3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results",
      "id": 136031226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials.  Shares of these drugmakers could jump if the data from the studies is positive.  Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials.",
      "url": "https://finnhub.io/api/news?id=481153932dcd0a118d9a0418223142728ca633111da836c0879efeeca1e73c97"
    }
  }
]